Veverimer 对合并代谢性酸中毒的糖尿病 CKD 患者血清碳酸氢盐与躯体功能的影响:随机对照试验亚组分析
本分析为一项 3 期多中心随机双盲安慰剂对照试验的事后亚组分析,纳入 196 例 eGFR 20–40 mL/min/1.73 m² 且伴代谢性酸中毒的 CKD 患者,治疗至 1 年。在糖尿病亚组中,第 52 周 veverimer 组血清碳酸氢盐升幅显著大于安慰剂组(4.4 对 2.9 mmol/L,P < 0.05),患者报告的躯体功能受限与客观体能测试亦显著改善。
要点
- 糖尿病合并 CKD 与代谢性酸中毒患者中,veverimer 显著升高血清碳酸氢盐。
- 第 52 周患者报告的躯体功能受限及重复坐立试验客观体能均显著改善。
- 该亚组分析提示 veverimer 可能同时改善代谢性酸中毒与躯体功能。
核心结论
- 在合并糖尿病的 CKD 与代谢性酸中毒患者中,veverimer 有效治疗代谢性酸中毒,并显著改善患者主观感受与躯体功能。
研究设计与样本
- 3 期多中心随机盲法安慰剂对照试验的事后亚组分析,共 196 例 CKD(eGFR 20–40 mL/min/1.73 m²)伴代谢性酸中毒患者,治疗至 1 年。
主要发现
- 第 52 周 veverimer 组糖尿病患者的平均血清碳酸氢盐升幅显著大于安慰剂组(4.4 对 2.9 mmol/L,P < 0.05)。
- 肾脏疾病生活质量-躯体功能域中患者报告的躯体功能受限(如步行数个街区、爬一层楼梯)在 veverimer 组较安慰剂组显著改善(+12.5 对 +0.3,P < 0.001)。
- 重复坐立试验的客观体能表现亦显著改善(P < 0.0001)。
临床怎么用
- 对合并代谢性酸中毒的糖尿病 CKD 患者,veverimer 可能同时改善酸中毒指标与躯体功能,为目前少有的可改善生活质量或躯体功能的干预方向。
局限性
- 本结果为事后亚组分析,样本量有限,需谨慎解读其外推性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metabolic acidosis is a complication of chronic kidney disease (CKD) that increases risk of CKD progression, and causes bone demineralization and muscle protein catabolism. Patients with diabetes are prone to metabolic acidosis and functional limitations that decrease quality of life. Veverimer, an investigational, non-absorbed polymer that binds and removes gastrointestinal hydrochloric acid, is being developed as treatment for metabolic acidosis. This post hoc subgroup analysis evaluated effects of veverimer on metabolic acidosis and physical function among patients with diabetes. METHODS: This was a Phase 3, multicenter, randomized, blinded, placebo-controlled trial in 196 patients with CKD (estimated glomerular filtration rate 20-40 mL/min/1.73 m2) and metabolic acidosis who were treated for up to 1 year with veverimer or placebo. RESULTS: At Week 52, veverimer-treated patients with diabetes (n = 70), had a significantly greater increase in mean serum bicarbonate than the placebo group (n = 57) (4.4 versus 2.9 mmol/L, P < 0.05). Patient-reported limitations of physical function on the Kidney Disease and Quality of Life-Physical Function Domain (e.g. walking several blocks and climbing a flight of stairs) improved significantly in the veverimer versus placebo group (+12.5 versus +0.3, respectively, P < 0.001) as did objective physical performance on the repeated chair stand test (P < 0.0001). CONCLUSIONS: Few interventions for patients with diabetes and CKD have successfully improved quality of life or physical functioning. Our study demonstrated that veverimer effectively treated metabolic acidosis in patients with diabetes and CKD, and significantly improved how these patients felt and functioned.
引用
- Mathur VS, Li E, Wesson DE, et al. Effects of veverimer on serum bicarbonate and physical function in diabetic patients with chronic kidney disease and metabolic acidosis: subgroup analysis from a randomized, controlled trial. Nephrol Dial Transplant. 2022. PMID: 34240198. doi:10.1093/ndt/gfab209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。